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Abstract 
 
Background and aims: The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was a nationwide 
cluster-randomised double-blind trial designed to demonstrate the effectiveness of pneumococcal conjugate 
vaccine in vaccinated children and indirect effects in unvaccinated populations. Together with the parallel 
carriage/AOM trial, over 47,000 children were enrolled, 52% of the initial target. We conducted a 
questionnaire study to find out which factors affected parents’ decision on their child’s study participation. 
Methods: A questionnaire designed to evaluate parents’ attitudes to vaccine trial participation in general and 
the FinIP trial in particular was mailed after the trial enrolment period had ended to parents of randomly 
selected children: 1,484 who participated in the trial and 1,485 who did not participate. 
Results: Altogether 1,438 parents (48%) responded to the questionnaire. The response rate was higher 
among FinIP participants (65%, 965/1,484) than among FinIP non-participants (32%, 473/1,485). The two 
most important reasons for giving consent to the FinIP trial were the potential benefit of immunisation against 
pneumococcal diseases (75% of consenters) and the promotion of the common good and public health 
(11%). The reasons reported as most important for declining consent were suspicions of vaccine safety 
(36%) and the double-blind trial design (12%). Up to 65% of the non-consenters declared that drug and 
vaccine trials should not be conducted in children at all.  
Conclusions: The expected health benefit for the child was by far the most important reason for consenting 
to the vaccine trial. Safety concern was the main reason for decline. Importance and necessity of clinical 
drug and vaccine trials among children and the rationale of the blinded studies should be thoroughly 
explained to the public. This may increase participation in future vaccine trials. 
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Introduction  
 
All clinical research is dependent upon the acceptance and consent of the study participants or their legal 
representatives. Enrolment of children in vaccine trials is especially challenging due to the involvement of 
healthy individuals with a low parental tolerance for any adverse effects, perceived low individual risk of 
acquiring the disease being prevented by vaccination and the need for a large sample size especially in 
phase III–IV trials.  
 
The Finnish Invasive Pneumococcal disease (FinIP) trial (NCT00861380) was a nationwide field trial 
designed to demonstrate the effectiveness of a new pneumococcal conjugate vaccine [1]. Since FinIP trial 
was a cluster-randomized trial aiming to evaluate also indirect effects of the pneumococcal vaccine, the 
number of participants needed was especially high to reach high vaccination coverage in the study clusters. 
Together with the parallel acute otitis media trial (AOM trial, NCT00839254) more than 47,000 children were 
enrolled, 52% of the initial target defined in the protocol. The percentage of families who accepted the 
invitation to the trial was lower than anticipated, even though the study participation was planned to be as 
easy as possible. The FinIP trial was conducted at local well-baby clinics during routine health check-up and 
vaccination visits. Furthermore, no laboratory samples or active monitoring of possible symptoms were 
required, as national health registers were used for the follow-up of outcomes.  
 
We conducted a questionnaire study to assess the perceptions and attitudes of the parents of the children 
invited to the trial to discover the reasons to consent or not to consent to the child’s participation in the study. 
The purpose was to identify success factors and barriers in research information and study conduct that 
might be taken into consideration in future vaccine trials.  
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Methods 
 
The FinIP trial was a nationwide phase III/IV cluster-randomised double-blind field trial conducted by the 
National Institute for Health and Welfare (THL). The enrolment period extended from February 2009 to 
October 2010. The aim of the trial was to investigate the direct and indirect effects of pneumococcal 
conjugate vaccine PHiD-CV10 (Synflorix™, GSK Vaccines) against pneumococcal diseases (invasive, 
pneumonia and otitis media). The trial design has been previously described [1]. Briefly, all children aged 
<19 months residing in the study area covering most of Finland were eligible if they had not received and 
were not expected to receive any of the study vaccines. The children were administered two to four doses of 
either the pneumococcal vaccine or a control vaccine (hepatitis A, Havrix™, or hepatitis B, Engerix-B™, GSK 
Vaccines). The control vaccine and the number of doses depended on child’s age at enrolment. All study 
vaccines were licensed in Finland before the trial began but they were not included in the national 
vaccination programme at the time of enrolment, except for specified risk groups. 
 
All age-eligible children living in the study areas were identified using data from the Population Register 
Centre. THL sent invitations to parents and/or guardians by mail (N~125,000). The mailed information 
package included the invitation (1 page) and a consent document (available as Supplement 1) with the full 
information sheet (6 pages) and a consent form filled with dummy details (1 page). Additionally, an open 
website (www.finip.fi) including all the information material was developed, and leaflets and posters were 
displayed at well-baby clinics and maternity hospitals. Furthermore, THL phone and e-mail services were 
available to parents.  
 
The trial was conducted at well-baby clinics (N=651) at municipal health centres by public health nurses 
(N~2,000) who are in charge of routine child health follow-up [2], including the vaccinations according to the 
national vaccination programme. Well-baby clinic services are free of charge, and nearly all families with 
under school-age children use them as scheduled [3]. Well-baby clinic nurses, and physicians when needed, 
provided verbal information during the scheduled visits and obtained the written informed consent from a 
parent willing to have the child enrolled in the trial. Nurses administered the study vaccines. THL study 
personnel educated the personnel of the well-baby clinics to conduct the trial according to good clinical 
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practice, conducted repeated follow-up visits at the WBCs and, if needed, provided instant advice to well-
baby clinic nurses via telephone and/or email. Furthermore, a secure website was developed with full study 
information and regular newsletters were sent by email as reminders of any topical issues.  
 
In addition to enrolment through well-baby clinics, the Tampere University Vaccine Research Centre 
conducted a parallel trial (AOM trial) with the same design for acute otitis media and nasopharyngeal 
carriage. Its participants were also followed for the outcomes of the FinIP trial [4].These subjects were 
enrolled at 15 dedicated study clinics located in the biggest cities in Finland. Additional differences in the 
practical conduct included sampling of nasopharyngeal swab specimens, and active follow-up for acute otitis 
media and safety.   
 
A questionnaire was designed to evaluate parents’ attitudes to drug trials in general and to the FinIP trial in 
particular. The questionnaire was based on questionnaires used in other similar studies [5-7]. It was tested 
and finalised according to feedback from study personnel, well-baby clinic nurses and families with age-
eligible children. The questionnaire translated into English is available as Supplement 2. 
 
Respondents were first asked whether their child had participated in the vaccine trial or not. If the child did 
not participate, we asked whether their child had an exclusion criterion or whether the parents were reluctant 
to consent to the child’s participation. The responses from parents whose child had an exclusion criterion 
were excluded from analysis. 
 
In the primary question, respondents were asked to rank one to three most important reasons for giving or 
declining consent to vaccine trial. In other sections of the questionnaire, parents were asked how the 
characteristics of the trial had influenced their decision, the characteristics of the information sources, 
parental attitudes towards clinical drug and vaccine trials, persons influencing parents’ decision, the parents’ 
feelings about the decision-making process, and background data (Supplement 2).  
 
Responses to most questions were scored using a seven-step Likert-type scale (steps from extremely 
important reason for participation to extremely important reason for refusing participation, Figure 2). For 
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some questions, we used five-step and three-step scales. The questions were designed to be analysed 
separately.  
 
According to the sample size calculation 440 responses were needed from both participants and non-
participants to achieve adequate power to show the possible differences between the groups. In previous 
questionnaire studies, the response rate among non-participants had been 30% to 50% [6-8]. Based on this 
we decided to select 1,500 non-participants and an equal number of participants as the target group of this 
study. After checking the addresses of the randomly selected subjects, the questionnaire was mailed to 
parents of 2,969 children invited to the FinIP trial. The first mailing took place in January 2011, four months 
after the enrolment of the vaccine trial had ended. Altogether 1,484 families with enrolled children received 
the questionnaire. Of them, 135 were enrolled in the AOM trial which enabled evaluation of potential 
differences of participants in this trial with a different enrolment and data collection methods. The 
questionnaire was re-mailed once to families who did not respond within one month after the first mailing. 
 
Families were invited to respond to the questionnaire either by mail or online, using their personal answering 
code. The questionnaire did not include any personal identification data and the answering code was used 
only for linking the FinIP vaccine trial consent date to the questionnaire data. Respondents were offered 
cinema tickets, lottery scratch cards or a donation to charity (~12€) as a compensation for responding. 
 
A positive statement after ethical review was obtained from the institutional review board of the National 
Institute for Health and Welfare. 
 
Statistical methods 
The responses are presented in two main groups: families participating in the FinIP or AOM trial (consenters) 
and families who refused to participate in the trial (non-consenters). For questions concerning the FinIP trial 
methods and consent document, the responses of AOM trial consenters were excluded from the analysis. 
 
The differences between consenters and non-consenters were compared with chi
2
–test and t-test. The 
responses to the Likert-type questions were plotted graphically, and differences between the groups were 
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analysed with Mann-Whitney U test. All analyses were conducted using IBM SPSS Statistics 21. P-value 
<0.05 was considered statistically significant. No corrections for multiple testing were performed. 
 
The questions which respondents had left unanswered were omitted from statistical testing, but their 
percentages are shown in the figures. For the primary question, i.e. ranking of reasons, responses with more 
than one reason marked as the most important were excluded from analysis. 
 
Results 
 
A response to the questionnaire was returned by 1,438 families (48%). The response rate was higher among 
FinIP participants (65%, 965/1,484) than among FinIP non-participants (32%, 473/1,485, p<0.001). The 
FinIP non-participants included 356 children whose parents had declined consent (non-consenters) and 117 
who had an exclusion criterion preventing participation (Supplement 3).  
 
The background information on the respondents is shown in Table 1. Over 90% of them were mothers. The 
average number of children per family was two. According to the questionnaire, single parents declined 
consent more often than families with two parents. The mother’s level of education affected participation. 
Both the lowest and highest educational attainment were more common among non-consenters than 
consenters (Table 1). The families who declined consent were more likely to belong to groups with lowest 
annual income than participating families (p<0.01). The majority of families (67%) reported that none of the 
family members had participated in any medical trial before the FinIP. 
 
The AOM trial consenters were more likely to live in a city or municipal centre than the FinIP consenters, as 
only children living near study clinics were invited to the AOM trial. None of the AOM trial consenters who 
responded to the questionnaire were single parents. In other respects, the AOM consenters did not differ 
from the FinIP consenters. 
 
The consenters trusted their well-baby-clinic nurse more than non-consenters. “I trust my own well-baby 
clinic nurse in matters related to my child’s health” was agreed or strongly agreed by 81% (771/956) of 
consenters and 68% (242/356) of the non-consenters (p<0.001).  According to the responses the consenters’ 
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children had received the vaccines offered by the well-baby clinic more often than the non-consenters, 97% 
vs 86%, p<0.001. 
 
The most common reason declared as the most important  for consenting was the potential benefit of 
immunisation against pneumococcal diseases (75%, 681/905), followed by the promotion of the common 
good (11%, 100/905). The main reasons for refusing consent were suspicion of vaccine safety (35%, 
111/321), and the double-blind trial setting (12%, 38/321, Figure 1).  
 
The same reasons to consent or decline participation were also seen in the Likert-type questions (Figure 2): 
77% (742/965) of the consenters reported that promoting the common good and public health had a positive 
impact on participation; 16% (121/742) of them thought that it was an extremely important reason to consent. 
Most non-consenters (68%, 241/356) reported that promoting the common good and public health was 
among reasons with no impact on the decision.  
 
The majority of non-consenters (66%, 235/356) responded that they would not agree to their own child 
participating in any research. A similar number of non-consenters (65%, 232/356) responded that drug or 
vaccine trials should not be conducted in children (Figure 2).  
 
More detailed results about the reasons affecting the willingness to consent to the FinIP trial, are given in 
Figure 2 and Supplement 4. In line with earlier responses the expected health benefit was seen as the most 
important reason to participate. The importance of participation being easy was apparent in the responses. 
The use of licensed vaccines and study conduct during routine well-baby clinic appointments were both at 
least positively impacting causes; also among non-consenters (Figure 2). 
 
Both consenters and non-consenters were satisfied with the study information received (Figure 3). The most 
important information sources for parents were the verbal information given by well-baby clinic nurse and the 
consent document. The consenters gave a positive assessment of the well-baby clinic nurses’ ability to 
describe the trial (Figure 3). Among non-consenters, the percentage of respondents who considered that the 
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well-baby clinic nurse had given them sufficient information about the trial and that the given information was 
clear was lower than among consenters, 42% vs. 90% and 46% vs. 90%, respectively (p<0.001, Figure 3). 
  
Both parents had input in the participation decision. The well-baby clinic nurse conducting the trial affected 
the parents’ decision. Anti-vaccine movement, social media discussions and other information sources had 
only a minor influence on the decision. Their influence was stronger among non-consenters: about 15% to 
20% of the non-consenters were somewhat influenced by the social media or anti-vaccine movement, 
whereas among consenters the percentage was around 10% (Figure 4). 
 
Discussion  
 
The potential personal health benefit for child was the main reason to consent participation in the FinIP trial. 
The finding was evident and in line with previous studies [9,10]. Promotion of the common good and public 
health was the second most important reason to participate. It can be interpreted as a form of altruism, which 
in previous studies has been discovered to be an important reason to participate in clinical trials [9,11-13]. 
 
The possible risks of trials have commonly been reported to be the dominating cause for declining consent 
[5,6,9,12,14]. For the present questionnaire, the safety concerns may have been even further inflated due to 
the special media attention on the association between pandemic flu vaccine and narcolepsy [15] at the time 
of the questionnaire study. Unexpected and often serious disease cases accused to be caused by 
vaccinations are eagerly brought up by the media. These suspicions, even if not evidence-based, affect the 
perceptions of the population. Therefore, steps to cope with these unpredictable potential media alerts 
should be planned proactively.  
 
A finding of serious concern was that over half of non-consenters were reluctant to accept drug or vaccine 
trials involving children. Provided that the non-consenters responding to questionnaire were a representative 
sample of all non-participants in the population there would have been almost 58 000 families (75% of the 
77 000 non-participants, supplement 3) that did not want to participate in FinIP vaccine trial. Of those 22% 
(figure 2), ~13 000 families, would think that opinion “drug and vaccine trials should not be conducted in 
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children” was an extremely important reason to decline consent. Furthermore, 16% (~9 000) of non-
participating families would say this opinion was an important reason to decline and even more families (27% 
~16 000) would assess the opinion to have a negative impact on consenting. Thus, considering that there 
were ~125 000 families with age eligible children in Finland at the time of the trial, these figures reveal that 
every third Finnish family with young children think that clinical trials in children are at least somewhat 
repellent. This should prompt scientists and health care professionals to inform the public about the 
importance of trials among children.  
 
Another significant observation was that blinded vaccine administration allocated in random was considered 
to have impacted participation negatively in nearly 40% of the consenters and in up to 60% of the non-
consenters. Randomisation and blinding of the study vaccine or drug are usually crucial in trials, their 
importance and practical meaning need to be clearly explained in the consent document and other 
information sources. Offering possibility for cross-over vaccination after the trial follow-up, when feasible, 
might alleviate some of the concerns related to random allocation and blinding.  
 
In several studies, the consenters’ understanding of the aims and methods of clinical trial have been better 
than the non-consenters’ [5,11,16]. The only way to increase understanding is adequate and clear 
information. The most important information source was the verbal information given by the well-baby clinic 
nurses. This was considered even more important than the written information accepted by ethical review 
board. Consenters thought that the nurses were able to describe the trial clearly and understandably. Most 
non-consenters skipped this question.  As the FinIP trial was kind of extra work on top of the routine work in 
well-baby clinics the nurses’ motivation to conduct trial varied by site. Most probably well-motivated nurses 
informed the parents better and thus recruited more children. In earlier questionnaire studies, the 
professionalism, motivation and other characteristics of personnel have been associated with the willingness 
to participate [11,17,18]. Likewise, the importance of the clearness of knowledge and attitudes of the health 
care personnel administering vaccines has been shown to affect vaccine coverage [19]. It was also seen in 
our study that consenters trusted the well-baby clinic nurses and adhered to the national vaccination 
program more than non-consenters. Thus, in trials and in preventive health care, the motivation of the 
employees is one of the most important issues affecting the success.  
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The consent document was the second most important information channel for parents. According to most 
respondents the consent document was easy to understand and included adequate information. About 40% 
thought the document was too long, and a similar percentage considered its length appropriate. The 
obligatory information specified in Declaration of Helsinki [20] and by national regulatory and ethics bodies 
often extends the consent documents and may lead to situation in which the consent becomes difficult to 
fully understand [21]. The challenge that is likely to continue at least in the near future is to balance the legal 
and regulatory requirements with the understandable length and content of the consents in a manner that 
would secure the rights of the eligible study participants.   
 
In the vast majority of cases both parents had influenced on the participation decision as expected. However, 
only one of them was requested to sign the consent form, which is compatible with the Finnish legislation. In 
practice, it may be difficult to get both parents to attend a vaccine trial appointment for the informed consent 
process, especially in large post-licensure studies. Our study showed that providing timely and adequate 
information for the decision-making is adequate to guarantee both parents’ opinions.  
 
Even though the social media has been seen as an important information source and opinion former, 
responses indicated that the FinIP participation decisions were not affected by it as much as anticipated. The 
influence of anti-vaccine movement was also quite low. However, the influence was higher among parents 
who declined consent. Thus, it is important that the facts of the trial can be found online to counter the 
possibly misrepresented study information published by organisations and/or persons against vaccines or 
trials. It might be beneficial to add peer experiences of participating persons or families to the web pages. 
This kind of informal information would at least increase the probability of finding positive information about 
studies and vaccines. So far the power of stories, often more effective than the scientific facts [22], have 
been used almost solely by anti-vaccine persons and movements [23-25]. Recently, also pro-vaccine parents 
have established websites and appeared in to the social media discussions [26,27]. 
 
Low income and low educational attainment decreased consenting. This may be associated with the low 
number of single parent families among the consenters, since most of the families with lowest incomes were 
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single parent families, and the single mothers had lower educational attainment than mothers living with a 
spouse. However, 10% of toddlers live with one parent in Finland [28], and thus single parents were under-
represented among questionnaire respondents. Therefore, it is possible that these families responded less 
often if they were consenters rather than consented less often. The higher number of non-consenters among 
highly educated mothers has been reported previously [5,11,14]. However, it has been suggested that highly 
educated parents may answer questionnaires more eagerly and feel that they have to explain their refusal 
[11]. 
 
The questionnaire was conducted months after the enrolment of the vaccine trial had ended. The time gap 
between the enrolment and the questionnaire may have affected the responses, as respondents may have 
not remembered in detail the reasons affecting their decision and what kind of information material they had 
received.  
 
An unavoidable bias in questionnaire studies is the lack of completeness in the response. In this study, we 
sent out nearly 3,000 questionnaires and received responses from half of recipients. This is roughly the 
percentage usually seen in similar studies [6-8,11]. Another important bias in questionnaire studies is the 
skewed distribution of the responses: the consenters respond significantly more often than non-consenters 
[6-8].  
 
Conclusion 
 
Common good and public health were important reasons to participate in the trial. However, study showed 
that achieving high recruitment proportion will be possible only by trial design that guarantees some personal 
benefit for every study subject. Safety concern was the main reason for decline.  
The study showed lack of information among the public on importance and necessity of clinical drug and 
vaccine trials in children. The rationale of the blinded study approach should be explained to the public, i.e. 
potential participants, in an understandable manner. The opportunity for such informing is not only when a 
new study is starting but also in the phase where research results are published to the general population. 
This might increase the willingness to participate in future clinical trials. 
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Legends of the table and figures 
 
Table 1. Background information on the respondents to the questionnaire among FinIP trial consenters and 
non-consenters 
 
Figure 1. The most important reasons to consent or to decline consent in the FinIP trial. 
 
 
Figure 2.  Influence of the general and vaccine-related reasons and the methods of the trial on the decision 
whether to consent or not. The responses of consenters and non-consenters differed significantly (Mann-
Whitney U test, p<0.001) for every question. AOM trial consenters were excluded from the analysis of the 
methods, their responses are available in supplement 4. 
 
 
Figure 3. Parents’ opinions on the various information sources used in the FinIP trial. Statistical significance 
tested with Mann-Whitney U test, p-values marked in the figure, NS = not significant. 
    
Figure 4. Parents’ responses on whose opinions had influence on their decision concerning the child’s 
participation in the trial. Statistical significance tested with Mann-Whitney U test, p-values marked in the 
figure, NS = not significant. 
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  Consenters Non-consenters   
Respondent      
Mother 500 52% 177 50%  
Father 22 2% 8 2%  
Both 15 2% 2 1%  
No answer* 428 44% 169 47%  
      
Mean (range) age of respondents, years 31,6 (19-48) 31,4 (20-44) 
  
Mean (range) number of children in the family 2,1 (1-12) 2,2 (1-14) 
 
 
     Single parents 26 3% 18 5% p<0.05 
 
     Previous participation in medical trials 
     No 642 67% 282 79% p<0.001 
Yes, at least one parent 171 18% 38 11% p<0.01 
Yes, at least one children 177 18% 41 12% p<0.01 
 
     Level of education, mother  
 Comprehensive school 33 3% 22 6% p<0.01 
Secondary level qualification  408 42% 143 40% 
 Lower university degree  321 33% 98 28% 
 University degree 196 20% 92 26% p<0.05 
Not known/ no answer 7 1% 1 0% 
       
Level of education, father       
Comprehensive school 65 7% 20 6%  
Secondary level qualification  504 52% 191 54%  
Lower university degree  214 22% 76 21%  
University degree 169 18% 64 18%  
Not known/ no answer 13 1% 5 1% 
       
Employment situation, mother  
 Student 54 6% 27 8% 
 Employee or entrepreneur 646 67% 220 62% 
 Unemployed or retired 33 3% 11 3% 
 Stay at home mother 160 17% 80 22% 
 No answer / multiple choices 72 7% 18 5% 
       
Employment situation, father       
Student 28 3% 11 3% 
 Employee or entrepreneur 837 87% 310 87%  
Unemployed or retired 41 4% 17 5%  
Stay at home father 12 1% 5 1%  
No answer / multiple choices 47 5% 13 4%  
      
Family's total annual gross income at the moment, EUR 
  < 20,000 69 7% 42 12% p<0.01 
20,000 – 40,000 283 29% 112 31% 
 40,000 – 60,000 339 35% 104 29% 
 60,000 – 80,000 158 16% 48 13% 
 >80,000 92 10% 31 9% 
 No answer 24 2% 19 5% 
 
 
     Residence 
     City centre 93 10% 45 13% 
 Suburb 442 46% 156 44% 
 Municipal centre  212 22% 71 20% 
 Sparsely populated area 205 21% 77 22% 
 Other / no answer 13 1% 7 2%   
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